论坛 › 天涯情感 › 2023年值得期待的抗癌黑科技——癌症疫苗、CAR-T疗法、电场疗法，你认识吗？

tw4ld6 发表于 2024-5-21 04:40:42

2023年值得期待的抗癌黑科技——癌症疫苗、CAR-T疗法、电场疗法，你认识吗？

<img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLZXqXZJzdOKx00zqj3HibBRZt3IKToSDtAR9kuKwOsYOOCibvibZlesoQicanoO1RCJSQNEj9bEgrq2g/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">关注<span style="color: black;">没</span>癌家园</strong><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfLZXqXZJzdOKx00zqj3HibBRqf41qPRLX0bc1ialndmjpeMY9Uzz17WbWEiaAAhU3GibjxIpxrr2fgGFQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;"><span style="color: black;">咱们</span>战癌到底</strong><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLZXqXZJzdOKx00zqj3HibBRZt3IKToSDtAR9kuKwOsYOOCibvibZlesoQicanoO1RCJSQNEj9bEgrq2g/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNg6KqSDRGkFCLqIzx6oQdnlvRFe5Kz6dTZgyJ6UmBQKNhTdJ5lSkK5tGD8eK5NzjRd1QkhHt5m9hA/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">随着<span style="color: black;">全世界</span>对癌症<span style="color: black;">科研</span>的<span style="color: black;">持续</span>深入，越来越多的抗癌新药和新技术<span style="color: black;">面世</span>，足以<span style="color: black;">掌控</span>晚期癌症的<span style="color: black;">发展</span>，<span style="color: black;">加强</span>生活质量，延长寿命，<span style="color: black;">乃至</span>让<span style="color: black;">非常多</span>生命即将终结的晚期癌症<span style="color: black;">病人</span>奇迹重生！正值2023年年中之际，众多抗癌“黑科技”发展势头迅猛，备受广大癌友们期待和关注。</span><span style="color: black;">就在前不久的6月2日~6日，美国临床肿瘤学会（ASCO）年会在美国芝加哥圆满召开。最为一年一度规模巨大的临床肿瘤学会议之一，这场国际盛会可谓是饕餮盛宴，会议上国内外<span style="color: black;">科研</span>学者齐聚一堂，分享着各自<span style="color: black;">行业</span>的<span style="color: black;">科研</span>成果，其中不乏惊艳的亮眼数据。</span><span style="color: black;"><span style="color: black;">没</span>癌家园<span style="color: black;">博主</span>今天就迫不及待地给<span style="color: black;">大众</span>介绍这些国际先进前沿新技术新疗法！<span style="color: black;">期盼</span><span style="color: black;">大众</span>在2023年能够积极抗癌，成功抗癌！</span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLTn8fW2ibXa2rSh54sQxHKGbqPASpFzR4j2d73fMxLrakksc8j7kFHs0icBjaax0qstT3gEK4FVvqA/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">癌症疫苗</strong></span></p><span style="color: black;">几十年来，癌症疫苗<span style="color: black;">已然</span><span style="color: black;">作为</span>免疫疗法的一种形式，<span style="color: black;">经过</span>刺激或恢复人体<span style="color: black;">自己</span>的免疫系统，来防止癌症发展或杀灭现有的肿瘤。</span><span style="color: black;">据《The Guardian（卫报）》10月16日<span style="color: black;">信息</span><span style="color: black;">叫作</span>，德国生物技术<span style="color: black;">机构</span>BioNTech的创始人在接受BBC采访时<span style="color: black;">叫作</span>，针对癌症的疫苗可能2030年前上市。</span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">获突破性疗法认定！mRNA疫苗让黑色素癌复发或死亡<span style="color: black;">危害</span>下降44%</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLUTgZ95j30T5EYGIg8BiavQfYL8Lljc0z3ex5fH03JJ5ic4zZB3IVoARpDEToR9x52W77AKWHDakJw/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">在2023年ASCO会议上，Moderna和MSD<span style="color: black;">颁布</span>了一项最新结果，证明当mRNA疫苗与Keytruda (<span style="color: black;">帕博利珠单抗，</span>pembrolizumab) 联合<span style="color: black;">运用</span>时，可改善远处<span style="color: black;">没</span>转移<span style="color: black;">存活</span>期 (DMFS)。</span><span style="color: black;">在KEYNOTE-942<span style="color: black;">科研</span>中，联合<span style="color: black;">开发</span>的基于<span style="color: black;">病人</span>肿瘤DNA的个体化治疗mRNA-4157/V940疫苗，<span style="color: black;"><strong style="color: blue;">将高危III/IV期黑色素瘤<span style="color: black;">病人</span>的远处转移或死亡<span style="color: black;">危害</span>降低65%</strong></span> (HR=0.347) ，与Keytruda联合<span style="color: black;">运用</span>时与单独<span style="color: black;">运用</span> Keytruda 相比，报告的不良事件和安全性与之前的<span style="color: black;">发掘</span>一致。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">正在进行的随机、开放标签 IIb 期<span style="color: black;">实验</span>的结果于 2022 年 12 月首次<span style="color: black;">颁布</span>，其结果足以让美国食品和<span style="color: black;">药品</span>管理局 (FDA) 授予突破性疗法认定，欧洲<span style="color: black;">药物</span>管理局(EMA)为联合疗法授予优先<span style="color: black;">药品</span> (PRIME) <span style="color: black;">叫作</span>号。两家<span style="color: black;">机构</span>计划在 2023 年<span style="color: black;">起步</span>一项 III 期<span style="color: black;">科研</span>，调查该组合<span style="color: black;">做为</span>高危黑色素瘤<span style="color: black;">病人</span>的辅助治疗。这些结果进一步说明了个体化新抗原疗法<span style="color: black;">有可能<span style="color: black;">作为</span>治疗黑色素瘤和其他癌症的新前沿疗法。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">早在</span><span style="color: black;">2023年2月23日，默沙东宣布，</span><strong style="color: blue;"><span style="color: black;">在研mRNA癌症疫苗mRNA-4157/V940联合Keytruda组合疗法获美国食品<span style="color: black;">药物</span>监督管理局（FDA）授予</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">突破性疗法认定</span></strong></span><span style="color: black;">，</span><strong style="color: blue;"><span style="color: black;">用于高危黑色素瘤<span style="color: black;">病人</span>接受完全切除术后的辅助治疗</span></strong><span style="color: black;">，与单独<span style="color: black;">运用</span><span style="color: black;">Keytruda相比，联合疗法能使<span style="color: black;">病人</span>的复发或死亡<span style="color: black;">危害</span>降低44%。</span></span></p><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">针对HPV阴性头颈癌<span style="color: black;">病人</span>，个体化新抗原疫苗TG4050表现优异</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbyEnYQRP0N5wSXjhZI9W45eeFkH32nb9HcTiaQKBje3S2Wt1ofzOTN9zA/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">这里</span>次ASCO大会上，Transgene和NEC<span style="color: black;">机构</span><span style="color: black;">颁布</span>了关于个体化新抗原癌症疫苗TG4050治疗HPV阴性头颈癌<span style="color: black;">病人</span>的1期临床<span style="color: black;">实验</span>的新数据。分析<span style="color: black;">表示</span>，<span style="color: black;">实验</span>中所有接受TG4050治疗的<span style="color: black;">病人</span>都产生了特异性免疫反应，正如额外免疫学测试的结果所证明的那样，并迄今为止保持<span style="color: black;">没</span>病状态。</span><strong style="color: blue;"><span style="color: black;">TG4050 是一种针对实体瘤<span style="color: black;">研发</span>的个体化免疫疗法，基于病毒载体个体化免疫治疗平台技术，并由NEC<span style="color: black;">长时间</span><span style="color: black;">累积</span>的人工智能（AI）专业知识<span style="color: black;">供给</span>支持。</span></strong><span style="color: black;">值得一提的是，此次<span style="color: black;">颁布</span>的数据<span style="color: black;">表示</span>，<span style="color: black;"><strong style="color: blue;">即使是<span style="color: black;">已然</span>被确认为PD-L1阴性或低表达的<span style="color: black;">病人</span>，<span style="color: black;">亦</span><span style="color: black;">一样</span>有理想的表现。</strong></span></span><span style="color: black;"><span style="color: black;">截止</span>2023年5月，头颈癌1期<span style="color: black;">实验</span>中已有32例<span style="color: black;">病人</span>进行了随机分组。<span style="color: black;"><strong style="color: blue;">所有接受TG4050治疗的16例<span style="color: black;">病人</span>保持缓解状态，中位随访时间为10.4个月。</strong></span>而对照组中有2例<span style="color: black;">拥有</span><span style="color: black;">类似</span>特性的<span style="color: black;">病人</span>产生复发，<span style="color: black;">另一</span>2例<span style="color: black;">病人</span><span style="color: black;">亦</span>表现出生化复发的迹象。<span style="color: black;">迄今</span>为止，该疫苗展现良好耐受性，<span style="color: black;">无</span><span style="color: black;">关联</span>严重不良事件的<span style="color: black;">出现</span>。Transgene和NEC计划该<span style="color: black;">实验</span>将在2024年中期实现18个月的中位随访，并进一步准备在2023年下半年<span style="color: black;">起步</span>头颈癌II期辅助<span style="color: black;">实验</span>。</span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbyQBChtOy8G8jtAYib09s3spxz7G0t0KFmsSR3EHb85E42r5nuZghKvqA/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">怎样</span>寻求个性化癌症疫苗治疗</strong></span><strong style="color: blue;">&gt;&gt;</strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">日前</span>，癌症疫苗中疗效及预防复发效果较为<span style="color: black;">明显</span>的当属</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">树突状细胞疫苗</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">及</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">个性化新抗原疫苗</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">等，在德国、日本<span style="color: black;">亦</span>有树突状细胞疫苗用于临床辅助治疗多种癌症，如肺癌、肝癌、肾癌、乳腺癌、皮肤癌等，这是癌症<span style="color: black;">病人</span>治疗的新<span style="color: black;">期盼</span>。</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">想寻求国内外治疗新技术<span style="color: black;">帮忙</span>的<span style="color: black;">病人</span>，</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">在经济<span style="color: black;">前提</span><span style="color: black;">准许</span>的<span style="color: black;">状况</span>下，<span style="color: black;">能够</span>先将病理报告、治疗经历及出院小结等资料提交至</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">进行初步<span style="color: black;">评定</span>。</span></strong></span><span style="color: black;"><strong style="color: blue;">点击下面<span style="color: black;">文案</span>链接查看实体瘤热门癌症疫苗临床<span style="color: black;">科研</span><span style="color: black;">发展</span></strong></span><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfJaeyWQxNqiavJVG7iaOJEmKy2cZ3iaibD9TITECeGe8QbKoQRGN85wpdzbxgSSU9QmfXwqHVJsXqg7GQ/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">HISTORY</strong>/<strong style="color: blue;">往期推荐</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">肿瘤疫苗大出圈！80%的乳腺癌<span style="color: black;">病人</span><span style="color: black;">存活</span>期超10年！12款新型疫苗有望拯救癌症<span style="color: black;">病人</span>！</strong></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">17年磨一剑！挑战致命脑癌，注射新型癌症疫苗后，<span style="color: black;">病人</span>存活时间最长已超8年！</strong></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">完全缓解后不可松懈，预防复发是<span style="color: black;">重要</span>！树突状细胞疫苗让癌症<span style="color: black;">病人</span><span style="color: black;">长时间</span>缓解，疗效持久！</strong></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">癌症有望被<span style="color: black;">解决</span>！具备治愈<span style="color: black;">潜能</span>的个性化新抗原疫苗实现治疗与预防复</strong></a><strong style="color: blue;">发双杀！</strong></p><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfKSAiahu31u2kgUl8AkPBh6nsTWSoWTia5fM3oXAicZzxl3AUgYiaBChRaAtfrqtZkmqHWDbubdUibDb3w/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbypjYcb6jacbSrrg1nDfP7mNGP5soS5XHxVian0kE76PtTl4PSmagoBicw/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">CAR-T疗法</strong></span></p><span style="color: black;"><span style="color: black;">日前</span>，CAR-T疗法是近年来最有前景的细胞免疫疗法之一，这项技术在治疗<span style="color: black;">各样</span>恶性肿瘤方面取得了巨大<span style="color: black;">发展</span>，已成功应用于多种血液恶性肿瘤的治疗。</span><span style="color: black;"><span style="color: black;">做为</span>一种</span><span style="color: black;"><strong style="color: blue;">“活的”<span style="color: black;">药品</span></strong></span><span style="color: black;">，CAR-T疗法与传统<span style="color: black;">药品</span>有着很大的区别。</span><span style="color: black;"><strong style="color: blue;">它</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">是一种治疗肿瘤的新型<span style="color: black;">精细</span>靶向疗法。</span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">经过</span>基因工程技术将T细胞激活，并装上定位导航<span style="color: black;">安装</span>CAR（肿瘤嵌合抗原受体），将T细胞这个普通“战士”改<span style="color: black;">导致</span></span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">“超级战士”</span></strong></span><strong style="color: blue;"><span style="color: black;">，即CAR-T细胞，</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">专门识别<span style="color: black;">身体</span>肿瘤细胞，并<span style="color: black;">有效</span>杀灭肿瘤细胞</span></strong></span><strong style="color: blue;"><span style="color: black;">，从而达到治疗恶性肿瘤的目的。</span></strong>与传统的化疗和造血干细胞移植相比，它对肿瘤细胞的杀伤更为<span style="color: black;">精细</span>，在<span style="color: black;">加强</span>疗效的<span style="color: black;">同期</span>大幅减轻了毒副<span style="color: black;">功效</span>。</span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">再战告捷！西达基奥仑赛可降低74%疾病<span style="color: black;">发展</span>或死亡<span style="color: black;">危害</span>！</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbyEnYQRP0N5wSXjhZI9W45eeFkH32nb9HcTiaQKBje3S2Wt1ofzOTN9zA/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">这里</span>次ASCO会议上，传奇生物<span style="color: black;">颁布</span>了III期CARTITUDE-4<span style="color: black;">科研</span>数据，结果<span style="color: black;">表示</span>，在中位随访16个月时，<strong style="color: blue;">与标准治疗<span style="color: black;">方法</span>（SOC）相比，<span style="color: black;">西达基奥仑赛（Cilta-cel，Carvykti）降低了既往接受过1~3线治疗且来那度胺耐药的多发性骨髓瘤成人<span style="color: black;">病人</span>74%的<span style="color: black;">疾患</span><span style="color: black;">发展</span>或死亡<span style="color: black;">危害</span></span></strong>（HR=0.26）。</span><span style="color: black;"><span style="color: black;">按照</span>此次<span style="color: black;">颁布</span>数据，<span style="color: black;">Cilta</span><span style="color: black;">-cel</span>治疗的<span style="color: black;">病人</span>中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期已超过15.9个月，而接受标准治疗的对照组<span style="color: black;">病人</span>，中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为11.8个月。</span><span style="color: black;">在既往接受过一线治疗<span style="color: black;">病人</span>中，降低了65%的<span style="color: black;">疾患</span><span style="color: black;">发展</span>或死亡<span style="color: black;">危害</span>（HR=0.35）。在次要终点中，cilta-cel组<span style="color: black;"><strong style="color: blue;">总缓解率（ORR）为85%</strong></span>，<span style="color: black;"><strong style="color: blue;">73%的<span style="color: black;">病人</span>达到完全缓解（CR）或更好，总体的微小残留病（MRD）阴性率达到61%。</strong></span>而在接受SOC治疗的<span style="color: black;">病人</span>中，ORR为67%，22%的<span style="color: black;">病人</span>达到CR或更好，MRD阴性率为33%。至12个月时，<span style="color: black;"><strong style="color: blue;">Cilta-cel治疗<span style="color: black;">病人</span>的<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>率为76%</strong></span>，标准治疗仅有49%。</span><span style="color: black;">在前线治疗<span style="color: black;">周期</span>，多发性骨髓瘤<span style="color: black;">始终</span>存在高度未被满足的需求。CARTITUDE-4<span style="color: black;">科研</span>结果<span style="color: black;">显示</span>，<span style="color: black;"><strong style="color: blue;">cilta-cel有可能为既往接受过1~3线治疗的复发或难治性多发性骨髓瘤<span style="color: black;">病人</span><span style="color: black;">供给</span>新的治疗<span style="color: black;">选取</span>。</strong></span></span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">肿瘤病灶完全缓解，mRNA疫苗联合CAR-T狙击实体瘤</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLiaMDqrBZMqbf5peCsw1lIbYPKzTJ2SsZrR5hVknk5ric4sYpIvTaqY043pdfX8rMJOcia1ICUmQr8w/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">BioNTech<span style="color: black;">机构</span><span style="color: black;">研发</span>的</span><span style="color: black;"><strong style="color: blue;">BNT211</strong></span><span style="color: black;">是</span><strong style="color: blue;"><span style="color: black;">靶向实体瘤的新一代CAR-T疗法。</span></strong><span style="color: black;"><strong style="color: blue;">它将靶向CLDN6抗原的CAR-T疗法与表达CLDN6抗原的mRNA疫苗CARVac（<strong style="color: blue;">这是一种独特的CAR-T细胞扩增mRNA疫苗</strong>）相结合。</strong></span><span style="color: black;">在2023年美国临床肿瘤学会（ASCO）会议上，<span style="color: black;">科研</span>人员更新了关于CLDN6 导向的 CAR-T 细胞疗法 BNT211 <span style="color: black;">没</span>论<span style="color: black;">可否</span>添加 CLDN6 编码 mRNA 疫苗 (CARVac)治疗CLDN6 阳性复发/难治性实体瘤<span style="color: black;">病人</span>的1/2a 期<span style="color: black;">实验</span>结果，<span style="color: black;">表示</span>出令人鼓舞的活动迹象和可控的安全性。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfLN69XM21uqBFeO7r7mfhBNLy98w1o8T934TcwAFoeDoBiabtYFQHaVZEPFUw0ebX3OjYG843iciaKiaw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">图源来自OnClive官网</span></strong></p><span style="color: black;">数据截止到2023年3月10日，在17例接受 BNT211 联合或不联合 CARVac 治疗的可<span style="color: black;">评定</span><span style="color: black;">病人</span>中，</span><span style="color: black;"><strong style="color: blue;">总客观缓解率（ORR）为 41%，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率（DCR）为65%。</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">1 名接受治疗的睾丸癌<span style="color: black;">病人</span><span style="color: black;">得到</span>了手术完全缓解。还有5例<span style="color: black;">病人</span>达到部分缓解（PR），其中 4 例为卵巢癌<span style="color: black;">病人</span>，1 例为其他肿瘤类型。</span></strong></span><span style="color: black;"><span style="color: black;">另外</span>，3名<span style="color: black;">病人</span>达到病情稳定（SD）。</span><span style="color: black;">
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">另外</span>，手动BNT211 队列的数据<span style="color: black;">亦</span>进行了更新。</p>
    </span><span style="color: black;">在2022年ESMO大会上<span style="color: black;">颁布</span>的数据<span style="color: black;">表示</span>，共纳入了22例<span style="color: black;">病人</span>（其中21例<span style="color: black;">病人</span>可<span style="color: black;">评定</span>疗效）。肿瘤指征<span style="color: black;">包含</span>睾丸癌（n=13）、卵巢癌（n=4）、子宫内膜癌（n=1）、输卵管癌（n=1）、肉瘤（n=1）、胃癌（n=1）和1例肿瘤原发不明。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">截止2022年8月16日，对21例可<span style="color: black;">评定</span><span style="color: black;">病人</span>的疗效<span style="color: black;">评定</span><span style="color: black;">表示</span>，</span><span style="color: black;"><strong style="color: blue;">最佳总缓解率 为 33%，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率为 67%</strong></span><span style="color: black;">，其中</span><span style="color: black;"><strong style="color: blue;">1例完全缓解（CR）、6例部分缓解（PR）和7例<span style="color: black;">病人</span>病情稳定（SD）。</strong></span><span style="color: black;">这<span style="color: black;">寓意</span>着，</span><span style="color: black;"><strong style="color: blue;">超过60%的<span style="color: black;">病人</span>病情<span style="color: black;">掌控</span>稳定或<span style="color: black;">明显</span>缩小30%以上，<span style="color: black;">乃至</span>完全消失！</strong></span></p><span style="color: black;">更新数据<span style="color: black;">表示</span>：<span style="color: black;">截止</span>2023年3月10日，在13例生殖细胞肿瘤<span style="color: black;">病人</span>中有3例<span style="color: black;">病人</span>有<span style="color: black;">连续</span>的临床获益。其中1例幸运的<span style="color: black;">病人</span>在单独<span style="color: black;">运用</span> BNT211 时<span style="color: black;">得到</span><span style="color: black;">连续</span>完全缓解（CR）。</span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLN69XM21uqBFeO7r7mfhBNEm3ZvUYvwSbshDwTMxMHytYhbib3ILh2LlU2Cztt1S5HmLBda32ofBA/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">在收集<span style="color: black;">科研</span>数据时，1例先前接受过六线化疗的睾丸癌<span style="color: black;">病人</span></span><span style="color: black;">仍<span style="color: black;">处在</span><span style="color: black;">连续</span>的完全缓解状态</span><span style="color: black;">。<span style="color: black;">科研</span>人员指出，这是一例基线时肿瘤块<span style="color: black;">很强</span>的<span style="color: black;">病人</span>，在CAR-T细胞治疗6周后<span style="color: black;">表示</span>出令人印象深刻的</span><span style="color: black;">肿瘤消退</span><span style="color: black;">，<span style="color: black;">仅</span></span></span><strong style="color: blue;"><span style="color: black;">12周</span></strong><span style="color: black;">，肺部的转移灶<span style="color: black;">所有</span>消失，评效达到</span><span style="color: black;"><strong style="color: blue;">完全缓解的状态</strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfL0IGiaEOrpp2dib0zgSCJmyicyFP7YiafPdI8u06pAzibHKmoVuYKPiaAfa5PauZKhPv3yxiatow8CbXy0Q/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;">睾丸癌典型<span style="color: black;">病人</span>治疗<span style="color: black;">状况</span></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">综上，BNT211临床<span style="color: black;">实验</span>结果初步证实，</span><span style="color: black;"><strong style="color: blue;">CLDN6 CAR-T细胞联合CAR-T的RNA疫苗（CARVac）在剂量探索<span style="color: black;">周期</span><span style="color: black;">表示</span>出良好的安全性，并<span style="color: black;">表示</span>出令人鼓舞的疗效。</strong></span><span style="color: black;">mRNA疫苗（CARVac）可用于改善CAR-T细胞的抗肿瘤<span style="color: black;">功效</span>，为利用CAR-T细胞治疗难治性实体瘤<span style="color: black;">供给</span>了一种新的策略。</span></p><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfKYVczQZhticBRqkGSgjDWffMY6654IBhYU257hA8Js32Q5kfxEsgktiaLC0MhYfXRrgzuNC8nQ3Mfg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">日前</span><span style="color: black;">没</span>癌家园医学部急招<span style="color: black;"><strong style="color: blue;"><span style="color: black;">B细胞淋巴瘤、T细胞淋巴瘤、T细胞白血病（T-ALL）、急性淋巴细胞白血病、非霍奇金淋巴瘤、肝癌、胰腺癌、结直肠癌、间皮瘤、卵巢癌等</span></strong></span>癌种！</strong></span><span style="color: black;"><strong style="color: blue;">想要<span style="color: black;">评定</span>病情<span style="color: black;">可否</span>能够接受CAR-T疗法可将<span style="color: black;">病理报告、治疗经历及出院小结等</span>提交至<span style="color: black;"><span style="color: black;">没</span>癌家园医学部400-626-9916</span>进行初步<span style="color: black;">评定</span>！</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNhygrMUvvMXhWqpQn05Nh7GoJWnrE2M0diaAPQQIr2pbnibnp5XrnU0Mpfq4LVnDHymiazmod1BRprjw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></strong></span></p><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbypjYcb6jacbSrrg1nDfP7mNGP5soS5XHxVian0kE76PtTl4PSmagoBicw/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">电场疗法</strong></span></p><span style="color: black;">戴个“头套”，通上电就能治疗癌症，你可能会嗤之以鼻，别开玩笑了！这岂不是天方夜谭？当然不是！这<span style="color: black;">便是</span>黑科技“肿瘤电场疗法”的治疗手段！</span><span style="color: black;">电场疗法（TTFields）</span><span style="color: black;">最早是有以色列理工学院的荣誉教授尤兰姆·帕耳提<span style="color: black;">大夫</span>(Dr. Yoram Palti)在2001年<span style="color: black;">开发</span>出的，一种用低强度电场治疗<span style="color: black;">脑肿瘤</span>的新疗法。&nbsp;这种疗法是利用交替的低强度电场，摧毁肿瘤细胞，<span style="color: black;">同期</span>减少健康组织<span style="color: black;">损害</span>，可很好地避免副<span style="color: black;">功效</span>影响<span style="color: black;">病人</span>生活质量。</span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">电场搭配免疫疗法强强联手，肺癌<span style="color: black;">病人</span>重燃长<span style="color: black;">存活</span><span style="color: black;">期盼</span>！</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfJUvVgsqVhShpM48WcB609zKJcTHUYdJC7leVk6aSDOVeUWCAWia6Cg3aLV5XW0S2eLW0ZQ9wFSzpA/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2023年6月7日，在美国临床肿瘤学会（ASCO）年会上，再鼎医药<span style="color: black;">颁布</span>了一项<span style="color: black;">评定</span>TTFields联合标准治疗用于非小细胞肺癌（NSCLC）的 LUNAR 临床III 期<span style="color: black;">科研</span>的阳性结果。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">1.与</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">标准治疗</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">相比，肿瘤电场治疗联合标准治疗<span style="color: black;">明显</span><span style="color: black;">供给</span>了<span style="color: black;">拥有</span><span style="color: black;">明显</span>临床<span style="color: black;">道理</span>和统计学<span style="color: black;">道理</span>的</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">3个月中位总<span style="color: black;">存活</span>期的改善</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">，且</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">未<span style="color: black;">增多</span>系统性毒性</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">。</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">2.</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">电场疗法联合免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂（PD-1）</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">在</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">中位总<span style="color: black;">存活</span>期</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">上实现前所未有的</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">8个月的<span style="color: black;">提高</span></span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">。</span></strong></span></p><span style="color: black;">Novocure 的最新<span style="color: black;">科研</span>被<span style="color: black;">叫作</span>为<span style="color: black;"><strong style="color: blue;">LUNAR<span style="color: black;">实验</span></strong></span>，<span style="color: black;">科研</span>人员在<span style="color: black;">全世界</span>范围内招募了 276名铂类疗法失败的晚期非小细胞肺癌<span style="color: black;">病人</span>。<span style="color: black;">她们</span>被随机分配接受当前的标准护理治疗（免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂或化疗<span style="color: black;">药品</span>多西紫杉醇或其中一种<span style="color: black;">药品</span>）与 TTFields的组合。</span><span style="color: black;">此次<span style="color: black;">科研</span>的结果<span style="color: black;">表示</span>：</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfJUvVgsqVhShpM48WcB609zXaWJGojh6k3icOpMsiajlsOAb9icDuzQiaYMYVlZRiay7Kl46KVVJLlNvdA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p><strong style="color: blue;"><span style="color: black;">各队列之间<span style="color: black;">病人</span>基线特征达到了很好的平衡：</span></strong><strong style="color: blue;"><span style="color: black;">1. 接受TTFields联合标准治疗的<span style="color: black;">病人</span>的</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">1年<span style="color: black;">存活</span>率为53%</span></strong></span><strong style="color: blue;"><span style="color: black;">，而仅接受标准治疗的<span style="color: black;">病人</span>为</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">42%</span></strong></span><strong style="color: blue;"><span style="color: black;">（P=0.04）。</span></strong><strong style="color: blue;"><span style="color: black;">2. 一项<span style="color: black;">拥有</span>里程碑<span style="color: black;">道理</span>的分析<span style="color: black;">显示</span>，接受过TTFields联合标准治疗的<span style="color: black;">病人</span></span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">3年<span style="color: black;">存活</span>率<span style="color: black;">加强</span>了近3倍，达到18%</span></strong></span><strong style="color: blue;"><span style="color: black;">，而仅接受标准治疗的<span style="color: black;">病人</span>为</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">7%</span></strong></span><strong style="color: blue;"><span style="color: black;">(P=0.015)。</span></strong><strong style="color: blue;"><span style="color: black;">3.接受TTFields联合标准治疗的<span style="color: black;">病人</span>的中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期(PFS)为</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">4.8个月</span></strong></span><strong style="color: blue;"><span style="color: black;">，而单独接受标准治疗的<span style="color: black;">病人</span>为</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">4.1个月</span></strong></span><strong style="color: blue;"><span style="color: black;">。</span></strong><span style="color: black;"><span style="color: black;">因为</span>免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂单药治疗<span style="color: black;">需求</span><span style="color: black;">病人</span>的PD-L1是高表达，<span style="color: black;">然则</span>PD-L1高表达的<span style="color: black;">病人</span>毕竟比较少。而</span><span style="color: black;"><strong style="color: blue;">肿瘤电场治疗联合标准治疗的分组则是比较<span style="color: black;">平衡</span>，PD-L1表达的高低状态在四个组的<span style="color: black;">病人</span>分配<span style="color: black;">平衡</span>。这<span style="color: black;">显示</span>，</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">各样</span>PD-L1表达的肺癌<span style="color: black;">病人</span>均可受益。</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/uicOLyYe0PeScA0Ycvo48r1eEyX9VoXpv7KhMLMp7MRKMOfsC1ibibGSnYT7SBpXtZOr3TP5ic4I5wCCTIWMUO4QeA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></span></p><span style="color: black;"><span style="color: black;">值得一提的是，</span><strong style="color: blue;"><span style="color: black;">这款创新疗法预计在2023年下半年向美国食品<span style="color: black;">药物</span>监督管理局（FDA）提交上市申请，向国家<span style="color: black;">药物</span>监督管理局（NMPA）提交上市许可<span style="color: black;">亦</span>将在下半年<span style="color: black;">起始</span>，让<span style="color: black;">咱们</span>拭目以待！</span></strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbyQBChtOy8G8jtAYib09s3spxz7G0t0KFmsSR3EHb85E42r5nuZghKvqA/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">Novocure<span style="color: black;">机构</span>此次<span style="color: black;">颁布</span>的<span style="color: black;">科研</span>结果划破了七年之痒，据该<span style="color: black;">机构</span><span style="color: black;">叫作</span>，其<span style="color: black;">科研</span>是<span style="color: black;">第1</span>个3期临床<span style="color: black;">实验</span>，<span style="color: black;">最少</span>能够<span style="color: black;">仔细</span>说明该疗法能够<span style="color: black;">明显</span><span style="color: black;">加强</span>铂耐药、转移性非小细胞肺癌<span style="color: black;">病人</span>的<span style="color: black;">存活</span>率。</span><span style="color: black;">Novocure 的执行主席 William Doyle在接受采访时说，肿瘤电场技术于2011年<span style="color: black;">得到</span>FDA<span style="color: black;">准许</span>用于治疗胶质母细胞瘤，<span style="color: black;">已然</span><span style="color: black;">研发</span>了20<span style="color: black;">数年</span>。“令人兴奋的是23年后，<span style="color: black;">咱们</span><span style="color: black;">此刻</span><span style="color: black;">已然</span>超越了大脑，并在身体的其他部位<span style="color: black;">表示</span>了<span style="color: black;">第1</span>个积极的3期结果”，他说：“<span style="color: black;">日前</span>已证明，这不仅适用于大脑的局部、特殊<span style="color: black;">状况</span>，<span style="color: black;">况且</span>能够<span style="color: black;">帮忙</span>肺癌<span style="color: black;">病人</span>，<span style="color: black;">乃至</span>是其他躯干实体瘤！”</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">相比美国的电场疗法，日本<span style="color: black;">做为</span>医疗技术发达的国家之一，依据电场原理引进另一种设备，<span style="color: black;">叫作</span>为</span><span style="color: black;"><strong style="color: blue;">ECCT</strong></span><span style="color: black;">，经济<span style="color: black;">前提</span>有限的<span style="color: black;">病人</span><span style="color: black;">能够</span><span style="color: black;">思虑</span>。</span></p>
    <h2 style="color: black; text-align: left; margin-bottom: 10px;">
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">必须</span><span style="color: black;">尤其</span>提醒<span style="color: black;">大众</span>的是，美国的电场疗法<span style="color: black;">叫作</span>为TTF，是被FDA<span style="color: black;">准许</span>的以及<span style="color: black;">得到</span>众多临床<span style="color: black;">实验</span>数据的权威肿瘤治疗方式。而</span><span style="color: black;"><strong style="color: blue;">日本的电场疗法<span style="color: black;">叫作</span>为ECCT依据电场的原理<span style="color: black;">开发</span>的，<span style="color: black;">日前</span>暂时<span style="color: black;">无</span>大型的临床<span style="color: black;">实验</span>数据，在日本被再生医疗法<span style="color: black;">准许</span>，<span style="color: black;">做为</span>癌症的辅助治疗设备，预防癌症复发，延长<span style="color: black;">存活</span>期。</strong></span><strong style="color: blue;"><span style="color: black;"><span style="color: black;">一般</span>ECCT被用于恶性胶质瘤（GBM）的<span style="color: black;">病人</span>，在手术后完成放化疗治疗后联合化疗<span style="color: black;">运用</span>。</span></strong></p>
    </h2>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">最后，<span style="color: black;">因为</span>这款设备在美国的<span style="color: black;">花费</span><span style="color: black;">非常</span>昂贵，<span style="color: black;">咱们</span><span style="color: black;">亦</span><span style="color: black;">期盼</span>这款突破性的疗法在中国上市后，能尽快纳入<span style="color: black;">医疗保险</span>，让<span style="color: black;">更加多</span>的病友能接受这款有效的疗法，战胜癌症！<strong style="color: blue;">关于电场疗法的<span style="color: black;">更加多</span>信息及申请，<span style="color: black;">大众</span><span style="color: black;">能够</span>致电</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</strong></span><span style="color: black;"><strong style="color: blue;">进行咨询。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：<a style="color: black;">电场疗法“引爆”癌细胞，罕见肿瘤<span style="color: black;">病人</span>仅剩1年寿命到<span style="color: black;">很久</span>存活，堪<span style="color: black;">叫作</span>奇迹！</a></span></strong></span></p><span style="color: black;"><strong style="color: blue;">本文为<span style="color: black;">没</span>癌家园原创，转载需授权</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">参考文献</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">1.https://www.pharmaceutical-technology.com/news/asco-2023-moderna-and-msds-personalised-vaccine-reduces-chances-of-melanoma-spreading/</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2.https://www.businesswire.com/news/home/20230605005619/en/Transgene-and-NEC-Present-New-Data-on-TG4050-an-Individualized-Cancer-Vaccine-Showing-it-Induces-Specific-Immune-Responses-against-Head-and-Neck-Carcinoma-at-ASCO-2023</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">3.https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA106?role=tab</span></p><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLXhkcwuViaWxYyThPQoDuYe5T0h10e3qIAFn5YhC0Jm5IDHSs5NuibDicyJgXUOaR0GAtlowtMibSkQg/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;"><span style="color: black;">没</span>癌家园提醒癌友们</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">国内细胞免疫治疗技术，<span style="color: black;">包含</span><span style="color: black;">CAR-T细胞（除上市的三款CAR-T外）、树突细胞疫苗、NK细胞、TILs细胞、TCR-T细胞治疗、癌症疫苗等技术</span>均<span style="color: black;">处在</span>临床<span style="color: black;">实验</span><span style="color: black;">周期</span>，未获准在医院正式<span style="color: black;">运用</span>。国内<span style="color: black;">病人</span><span style="color: black;">能够</span>参加正规临床<span style="color: black;">实验</span>，在<span style="color: black;">大夫</span>的监管下<span style="color: black;">运用</span>，<span style="color: black;">没</span>癌家园网不<span style="color: black;">举荐</span><span style="color: black;">病人</span>冒然尝试任何医疗<span style="color: black;">公司</span>和<span style="color: black;">开发</span><span style="color: black;">公司</span>的收费治疗。</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKQpfMfOyKniaNUB3dhtGJpwd5K2DzsDnr1QXDxOgNBTQhaPgPdut3yscnmZjhiakE4YLibWQWCGS8RQ/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">热门<span style="color: black;">举荐</span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p><strong style="color: blue;">HISTORY</strong>/<strong style="color: blue;">往期精彩<span style="color: black;">文案</span><span style="color: black;">举荐</span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">嫌放疗副<span style="color: black;">功效</span>大？<span style="color: black;">脑肿瘤</span>、肺癌、食管癌及儿童肿瘤等不妨考</strong></a><strong style="color: blue;">虑质子治疗，疗效和<span style="color: black;">存活</span>质量双<span style="color: black;">保证</span>！</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">癌症治疗是场拉锯战！超90%的<span style="color: black;">病人</span>死于复发转移，细胞疗法助力“重建免疫系统”！</strong></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">CAR-T疗法<span style="color: black;">解决</span>实体瘤再传捷报！瞄准前列腺癌、胰腺癌、肝癌、胃癌，火力全开！</strong></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">免疫失调成压垮癌症<span style="color: black;">病人</span>最后一根稻草，<span style="color: black;">怎样</span><span style="color: black;">加强</span>免疫力持久抗癌，专家<span style="color: black;">最终</span>说出真相</strong></a></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">扫码关注<span style="color: black;">没</span>癌家园</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">我帮你抗癌，你关注我到<span style="color: black;">恢复</span>~</p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">点分享</strong><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">点<span style="color: black;">保藏</span></strong><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">点点赞</strong><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">点在看</strong>

aikangjian 发表于 2024-9-4 05:17:08

请问、你好、求解、谁知道等。

星☆雨 发表于 2024-9-9 08:03:48

楼主节操掉了，还不快捡起来！

nqkk58 发表于 2024-11-1 07:30:38

说得好啊！我在外链论坛打滚这么多年，所谓阅人无数，就算没有见过猪走路，也总明白猪肉是啥味道的。

4zhvml8 发表于 2024-11-1 16:51:50

谢谢、感谢、感恩、辛苦了、有你真好等。

查看完整版本: 2023年值得期待的抗癌黑科技——癌症疫苗、CAR-T疗法、电场疗法，你认识吗？